n Cardiovascular Journal of South Africa - Rosuvastatin receives FDA approval : drug trends in cardiology

Volume 14, Issue 5
  • ISSN : 1680-0745



Extracted from text ... 286 AstraZeneca has announced that its new cholesterol-lowering medication, rosuvastatin calcium, which has been shown to lower LDL cholesterol by up to 63%, has received approval from the US Food and Drug Administration (FDA) as an adjunct to diet for the treatment of various lipid disorders, including primary hypercholesterolaemia, mixed dyslipidaemia and isolated hypertriglyceridaemia. This follows the successful advisory committee meeting held in the US in July 2003, where the committee voted unanimously to recommend the approval of rosuvastatin. Rosuvastatin is the newest member of the cholesterol-lowering statin class (HMG-CoA reductase inhibitors) of drug therapy. In addition to its LDL (low-density ..

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error